<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939326</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-GL201</org_study_id>
    <nct_id>NCT02939326</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonti, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bonti, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar
      frown lines (GL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study of EB-001 to measure safety and efficacy in GL. Single doses of EB- 001
      administered through IM injection into procerus at midline and the medial and lateral
      corrugators will be assessed in healthy subjects with glabellar frown lines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">July 12, 2017</completion_date>
  <primary_completion_date type="Actual">July 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS).</measure>
    <time_frame>After single injection treatment up to 42 days</time_frame>
    <description>Subjects Achieving a 2 Grade Response At Maximum Frown On Any Study Day By Dose using the Facial Wrinkle Scale (FWS)
The FWS is a four-point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe.
Each scale is a four-point photonumeric scale based on photographs incorporating each aspect to be evaluated in a stepwise manner.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Glabellar Frown Lines (GL)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebo
Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 1 (1X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001
Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 2 (3X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 3X Dose 1
Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 3 (9X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 9X Dose 1
Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 4 (12X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 12X Dose 1
Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 5 (16X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 16X Dose 1
Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 6 (21X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 7 (28X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001, 28X Dose 1
Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB-001 injection</intervention_name>
    <arm_group_label>EB-001 Dose 1 (1X)</arm_group_label>
    <arm_group_label>EB-001 Dose 2 (3X)</arm_group_label>
    <arm_group_label>EB-001 Dose 3 (9X)</arm_group_label>
    <arm_group_label>EB-001 Dose 4 (12X)</arm_group_label>
    <arm_group_label>EB-001 Dose 5 (16X)</arm_group_label>
    <arm_group_label>EB-001 Dose 6 (21X)</arm_group_label>
    <arm_group_label>EB-001 Dose 7 (28X)</arm_group_label>
    <other_name>Botulinun Toxin Type E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated IRB-approved informed consent form (ICF).

          2. Men or women between the ages of 18 and 60, inclusive.

          3. Subjects in good health as determined by medical history, physical and focused
             neurological examinations, clinical laboratory studies, electrocardiograms (ECGs),
             vital signs, and Investigator's judgement.

          4. Presence of bilaterally symmetrical GL of moderate to severe rating at maximum frown,
             as measured using FWS by both the Investigator and subject prior to study treatment.

          5. Subjects with sufficient visual acuity without the use of eyeglasses (contact lens use
             acceptable) to accurately assess their facial wrinkles as determined by Investigator's
             judgement.

          6. Women of child bearing potential must not be pregnant, lactating, or planning to
             become pregnant during the study.

          7. Women of non-childbearing potential must be either postmenopausal (at least 12
             consecutive months of amenorrhea) or surgically sterile (e.g., tubal ligation,
             hysterectomy, etc.).

          8. Women of childbearing potential agreeing to use dual methods of contraception from the
             day of dosing until 3 months afterwards. Female subjects using oral contraception must
             have initiated treatment at least 2 months prior to the day of dosing.

          9. Male subjects with partner(s) of childbearing potential agreeing to use dual methods
             of contraception from the day of dosing until 3 months afterwards, and to no sperm
             donation from day of dosing until 3 months afterwards.

         10. Willing and able to complete protocol requirements and instructions, which include
             completion of all required visits.

        Exclusion Criteria:

          1. Any condition that precludes a subject's ability to comply with study requirements,
             including completion of the study visits or inability to read, understand, and/or
             self-assess GL severity using FWS.

          2. Any uncontrolled systemic disease or other medical condition.

          3. Any medical condition that may put the subject at increased risk with exposure to
             botulinum toxin of any serotype, including diagnosed myasthenia gravis, Eaton-Lambert
             syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere
             with neuromuscular function.

          4. Current or previous botulinum toxin treatment of any serotype.

          5. Anticipated need for treatment with botulinum toxin of any serotype for any reason
             during the study (other than study treatment).

          6. Known immunization or hypersensitivity to any botulinum toxin serotype.

          7. Known allergy or sensitivity to any of the components of the study treatments, or any
             materials used in the study procedures.

          8. Any of the following procedures or treatments occurring within the specified period
             prior to screening:

               -  3 months: Non-ablative resurfacing laser or light treatment, microdermabrasion,
                  or superficial peels.

               -  6 months: Any facial cosmetic procedure with medium depth to deep facial chemical
                  peels (e.g., trichloroacetic acid [TCA] and phenol), or mid facial or periorbital
                  laser skin resurfacing.

               -  6 months: On topical retinoid therapy and/or topical hormone cream applied to the
                  face, who have not been on a consistent dose regimen and are unable to maintain
                  the same regimen for the study.

               -  12 months: Mid-facial or periorbital treatment with non-permanent soft tissue
                  fillers.

               -  12 months: On oral retinoid therapy.

          9. Prior periorbital surgery, facial lift (full face or mid face), brow lift, or related
             procedures (e.g., eyelid [blepharoplasty] and/or eyebrow surgery).

         10. Prior mid face or periorbital treatment with permanent soft tissue fillers, synthetic
             implantation (e.g., Gore-Tex®), and/or autologous fat transplantation.

         11. Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick
             sebaceous skin.

         12. The inability to substantially lessen facial rhytides (fixed lines) even by physically
             spreading them apart, as determined by the Investigator.

         13. Permanent make-up that would interfere with the assessment of facial wrinkles.

         14. Subjects who, in the Investigator's opinion, are unable or unwilling to maintain their
             standardized skin care regimen throughout the study period.

         15. Any eyebrow or eyelid ptosis at baseline as determined by the Investigator.

         16. Infection or skin disorder at the injection sites.

         17. History of facial nerve palsy.

         18. Recent history (within 6 months of screening) of alcohol or drug abuse based on the
             Investigator's judgement.

         19. Anticipated need for surgery or overnight hospitalization during the study. Current
             enrollment in an investigational drug or device study or participation in such a study
             within 30 days or 5 half-lives of the drug, whichever is longer, of entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earvin Liang</last_name>
    <role>Study Director</role>
    <affiliation>Bonti, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin, MD Medical Associates, INC.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <results_first_submitted>October 17, 2018</results_first_submitted>
  <results_first_submitted_qc>January 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02939326/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
Placebo injection</description>
        </group>
        <group group_id="P2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection</description>
        </group>
        <group group_id="P3">
          <title>EB-001 Dose 2 (3X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 3X Dose 1</description>
        </group>
        <group group_id="P4">
          <title>EB-001 Dose 3 (9X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 9X dose 1</description>
        </group>
        <group group_id="P5">
          <title>EB-001 Dose 4 (12X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 12X Dose 1</description>
        </group>
        <group group_id="P6">
          <title>EB-001 Dose 5 (16X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 16X Dose 1</description>
        </group>
        <group group_id="P7">
          <title>EB-001 Dose 6 (21X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 21X Dose 1</description>
        </group>
        <group group_id="P8">
          <title>EB-001 Dose 7 (28X)</title>
          <description>Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
EB-001 injection 28X Dose 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
Placebo injection</description>
        </group>
        <group group_id="B2">
          <title>EB-001 Dose 1</title>
          <description>1st Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B3">
          <title>EB-001 Dose 2</title>
          <description>2nd Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B4">
          <title>EB-001 Dose 3</title>
          <description>3rd Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B5">
          <title>EB-001 Dose 4</title>
          <description>4th Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B6">
          <title>EB-001 Dose 5</title>
          <description>5thDose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B7">
          <title>EB-001 Dose 6</title>
          <description>6th Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B8">
          <title>EB-001 Dose 7</title>
          <description>7th Dose in escalation paradigm.
Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="8.48"/>
                    <measurement group_id="B2" value="52.0" spread="5.43"/>
                    <measurement group_id="B3" value="39.4" spread="16.13"/>
                    <measurement group_id="B4" value="52.2" spread="9.36"/>
                    <measurement group_id="B5" value="50.8" spread="6.50"/>
                    <measurement group_id="B6" value="45.4" spread="11.39"/>
                    <measurement group_id="B7" value="53.2" spread="4.66"/>
                    <measurement group_id="B8" value="42.6" spread="10.26"/>
                    <measurement group_id="B9" value="47.9" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS).</title>
        <description>Subjects Achieving a 2 Grade Response At Maximum Frown On Any Study Day By Dose using the Facial Wrinkle Scale (FWS)
The FWS is a four-point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe.
Each scale is a four-point photonumeric scale based on photographs incorporating each aspect to be evaluated in a stepwise manner.</description>
        <time_frame>After single injection treatment up to 42 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>EB-001 Dose 1 (1X)</title>
            <description>1st Dose in escalation paradigm.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O3">
            <title>EB-001 Dose 2 (3X)</title>
            <description>2nd dose in escalation paradigm, 3X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O4">
            <title>EB-001 Dose 3 (9X)</title>
            <description>3rd Dose in escalation paradigm, 9X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O5">
            <title>EB-001 Dose 4 (12X)</title>
            <description>4th Dose in escalation paradigm, 12X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O6">
            <title>EB-001 Dose 5 (16X)</title>
            <description>5th Dose in escalation paradigm, 16X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O7">
            <title>EB-001 Dose 6 (21X)</title>
            <description>6th Dose in escalation paradigm, 21X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
          <group group_id="O8">
            <title>EB-001 Dose 7 (28X)</title>
            <description>7th Dose in escalation paradigm, 28X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS).</title>
          <description>Subjects Achieving a 2 Grade Response At Maximum Frown On Any Study Day By Dose using the Facial Wrinkle Scale (FWS)
The FWS is a four-point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe.
Each scale is a four-point photonumeric scale based on photographs incorporating each aspect to be evaluated in a stepwise manner.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
Placebo injection</description>
        </group>
        <group group_id="E2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="E3">
          <title>EB-001 Dose 2 (3X)</title>
          <description>2nd dose in escalation paradigm, 3X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="E4">
          <title>EB-001 Dose 3 (9X)</title>
          <description>3rd Dose in escalation paradigm, 9X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="E5">
          <title>EB-001 Dose 4 (12X)</title>
          <description>4th Dose in escalation paradigm, 12X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="E6">
          <title>EB-001 Dose 5 (16X)</title>
          <description>5th Dose in escalation paradigm, 16X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area</description>
        </group>
        <group group_id="E7">
          <title>EB-001 Dose 6 (21X)</title>
          <description>6th Dose in escalation paradigm, 21X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
        <group group_id="E8">
          <title>EB-001 Dose 7 (28X)</title>
          <description>7th Dose in escalation paradigm, 28X Dose 1.
Single Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wajdie Ahmad</name_or_title>
      <organization>Bonti</organization>
      <phone>9493796569</phone>
      <email>wajdie@bonti.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

